FGP
MPLT

Freestone Grove Partners’s MapLight Therapeutics MPLT Stock Holding History

Freestone Grove Partners’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.05M Sell
168,912
-145,045
-46% -$4.17M 0.04% 332
2026
Q1 		$6.38M Buy
313,957
+130,186
+71% +$2.33M 0.05% 313
2025
Q4 		$3.23M Buy
+183,771
New +$3.08M 0.02% 378

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Freestone Grove Partners's MPLT Position: Q2 2026 in Review

Freestone Grove Partners reduced its MapLight Therapeutics (MPLT) stake by 46% in Q2 2026, selling an estimated $4.17M and leaving 168,912 shares worth $6.05M. The position accounts for 0.04% of the portfolio, ranked #332.

Freestone Grove Partners first reported a position in MPLT in Q4 2025 and has held it in 3 quarters since. The position peaked at $6.38M in Q1 2026. 100 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Freestone Grove Partners held 168,912 shares of MapLight Therapeutics worth $6.05M as of Q2 2026.
  • Freestone Grove Partners sold 145,045 MapLight Therapeutics shares in Q2 2026, an estimated $4.17M.
  • MapLight Therapeutics made up 0.04% of Freestone Grove Partners's portfolio in Q2 2026, its #332 holding.
  • Freestone Grove Partners first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Freestone Grove Partners's MapLight Therapeutics position peaked at $6.38M in Q1 2026.
  • 100 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.